People: TranS1 Inc (TSON.W)

TSON.W on CBOE When Trading NASDAQ Global Select Market

1.58USD
21 May 2013
Price Change (% chg)

$-0.10 (-5.95%)
Prev Close
$1.68
Open
$1.61
Day's High
$1.61
Day's Low
$1.58
Volume
200
Avg. Vol
87
52-wk High
$3.16
52-wk Low
$1.58

Search Stocks

Summary

Name Age Since Current Position

Paul LaViolette

 2012 Independent Chairman of the Board

Ken Reali

 46 2011 President, Chief Executive Officer, Director

Joseph Slattery

 47 2010 Chief Financial Officer, Executive Vice President

Rick Feiler

 52 2010 Vice President - Marketing

Stephanie Fitts

 2012 Vice President - Regulatory, Quality and Compliance

Stephen Ainsworth

 42 2010 Vice President - Research & Development

Mukesh Ramchandani

 46 2011 Vice President - Business and Market Development

Mark Stautberg

 53 2013 Director

Michael Carusi

 47 2003 Independent Director

Jeffrey Fischgrund

 51 2012 Independent Director

Jonathan Osgood

 63 2002 Independent Director

James Shapiro

 54 2005 Independent Director

David Simpson

 65 2010 Independent Director
» Insider Trading

Biographies

Name Description

Paul LaViolette

 Mr. Paul A. LaViolette is Independent Chairman of the Board of TranS1 Inc. He resigned as Lead Director of the company effective May 3, 2012. He has served as a member of Board of Directors of TranS1 Inc., since August 2008. Mr. LaViolette became a venture partner at SV Life Sciences in January 2009 and brings over 28 years of global medical technology marketing and general management experience. He was most recently Chief Operating Officer at Boston Scientific Corporation, or BSC, an $8 billion medical device leader. During his 15 years at BSC, he served as Chief Operating Officer, Group President, President-Cardiology and President-International as the company grew its revenues by over 20 times. Mr. LaViolette integrated two dozen acquisitions and led product development, operations and worldwide commercial organizations. He previously held marketing and general management positions at CR Bard, and various marketing roles at Kendall (Tyco). He previously served on the boards of Urologix, Percutaneous Valve Technologies and AdvaMed, and currently serves on the boards of Direct Flow Medical, Cameron Health, Conceptus, DJO Global, ValenTx, Inc., DC Devices, and Thoratec. He currently serves on the compensation committee of Thoratec, ValenTx, and Direct Flow Medical and on the audit committee of Conceptus. Mr. LaViolette received a B.A degree in Psychology from Fairfield University and an M.B.A. degree from Boston College.

Ken Reali

 Mr. Kenneth Reali is President, Chief Executive Officer, Director of TranS1 Inc. He has been Chief Executive Officer and a member of Board since January 4, 2011 and President since January 2010. Mr. Reali was initially hired by the company as President and Chief Operating Officer in January 2010. He joined the company from Smith & Nephew where he spent five years in various general management roles, including most recently as Senior Vice President and General Manager of the Biologics and Clinical Therapies Business. Prior to joining Smith & Nephew, Mr. Reali held senior marketing, sales and product development positions of increasing responsibility at Stryker for seven years. Prior to joining Stryker, Mr. Reali worked as a sales representative and marketing product manager at Biomet for eight years. Mr. Reali received a B.S. degree in Business from Valparaiso University.

Joseph Slattery

 Mr. Joseph P. Slattery is Chief Financial Officer, Executive Vice President of TranS1 Inc. Mr. Slattery served as a member of Board from November 2007 until April 2010 and resigned in connection with his appointment as an officer. From October 1, 2006 through August 3, 2007, Mr. Slattery served as Chief Financial Officer and Senior Vice President of Finance and Information Systems of Digene Corporation, a molecular diagnostics company that was acquired by Qiagen, N.V. in August, 2007. Prior to being appointed Chief Financial Officer, he served as Senior Vice President, Finance and Information Systems, beginning in September 2002. Previously, he served as Vice President, Finance, from July 1999 to September 2002 and as Controller from February 1996 to July 2000. Mr. Slattery served on the board of directors of Micromet, Inc., a publicly-held biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, which was acquired by Amgen in March 2012, and CVRx, Inc. a privately-held company developing implantable technology for the treatment of hypertension and heart disease. Mr. Slattery received a B.S. degree in Accountancy from Bentley University and is a Certified Public Accountant.

Rick Feiler

 Mr. Rick Feiler is Vice President - Marketing of TranS1 Inc. Mr. Feiler was hired by the company initially as a clinical sales manager in 2006 and has been serving as Director of Marketing since November 2007. Prior to his employment with the company, Mr. Feiler was a regional sales director for Inlet Medical, Inc., a medical device company that specializes in minimally interventional laparoscopic products, from 2005 through 2006, and was an representative at SurgRx, Inc., a medical device company that provides tissue sealing and hemostasis systems for laparoscopic and open surgery, from 2004 to 2005. Mr. Feiler has over twenty years of experience in sales management, field sales and marketing with medical device companies. Mr. Feiler earned a B.A. in Biochemistry and Molecular/Cellular and Developmental Biology from the University of Colorado and an M.B.A. degree from the J. L. Kellogg Graduate School of Management at Northwestern University.

Stephanie Fitts

 Dr. Stephanie M. Fitts, Ph.D. has been appointed as Vice President - Regulatory, Quality and Compliance of TranS1 Inc., effective 17 September 2012. Dr. Fitts has nearly twenty years of medical device experience having worked in the areas of clinical research, regulatory, quality and compliance. For the past nine years, Dr. Fitts worked at Stryker Orthopaedics, a medical technology company that offers an array of medical technologies, including reconstructive, medical, surgical, and spine products. During her time at Stryker, she served in multiple leadership positions, including most recently as Senior Director, Regulatory Affairs and Compliance and, from 2008 until 2011, as Director, Regulatory Affairs and Compliance. Prior to her time at Stryker, she served as Senior Clinical Program Manager at Medtronic, Inc. from 2000 until 2003. Prior to that, Dr. Fitts held positions at Cardiac Rhythm Management and Telectronics Pacing Systems. Dr. Fitts holds a B.S. degree in Engineering Science from the University of Virginia, and a Ph.D in Bioengineering from the Pennsylvania State University.

Stephen Ainsworth

 Dr. Stephen D. Ainsworth, Ph.D., is Vice President - Research & Development of TranS1 Inc. Dr. Ainsworth was hired by the company initially as a Senior Research and Development Engineer in 2002 and has been serving as Director of Product Development since 2008. Prior to his employment with the company, Dr. Ainsworth was a Senior Biomedical Scientist for Closure Medical Corporation, a company that develops and manufactures biomaterial based medical devices, and a Research and Design Engineer from 2000 through 2002 for Coalescent Surgical, Inc., a medical device company with a focus in creating minimally invasive anastomotic devices for use during coronary artery bypass surgery. Prior to 2000, Dr. Ainsworth was a Stent Technical Leader and Design Engineer for Guidant Corporation, a medical device company with a focus in cardiovascular medical products. Dr. Ainsworth has over 15 years of research and development experience with medical device companies. He earned his B.S. degree in Mechanical Engineering from Rensselaer Polytechnic Institute, and his M.S. and Ph.D., both in Bioengineering from Clemson University.

Mukesh Ramchandani

 Mr. Mukesh Ramchandani is Vice President - Business and Market Development of TranS1 Inc. Prior to that, he was Vice President of Business Development since June 2008. Mr. Ramchandani has over 15 years experience in the life science industry, with experience ranging from research to marketing, business development and corporate strategy. Prior to joining the companys, Mr. Ramchandani was at Kowa Research Institute, a US affiliate of a Japanese pharmaceutical company, Kowa Company Ltd. At Kowa, Mr. Ramchandani was responsible for all in-licensing, out-licensing and acquisitions. Prior to Kowa, Mr. Ramchandani started a device import and sales company called OBX Medical. Mr. Ramchandani also served at Baxter for 5 years, starting as a Senior Marketing Manager and for the last 3 years as Director, Global New Business. Mr. Ramchandani was also part of the Drug Discovery team at Pfizer from 1990 through 1994. Mr. Ramchandani received a B.S. in Chemistry from Campbell University, a M.S. in Organic Chemistry from East Carolina University and an M.B.A. from UNC-Chapel Hill’s Kenan-Flagler School of Business.

Mark Stautberg

 Mr. Mark T. Stautberg has been appointed as Director of TranS1 Inc. He currently serves as a sales and marketing consultant for multiple medical device companies. From 2004 to 2012, he served as a consultant to Boston Scientific Corporation's Cardio Rhythm Vascular Division. Prior to his service as a consultant, Mr. Stautberg was employed by Boston Scientific's Cardiovascular Division, serving as Senior Vice President of Sales from 1998 to 2004 and in other positions from 1991 to 1998. Mr. Stautberg previously served on the board of directors and as a consultant of Sealing Solutions, Inc., a vascular sealing company, from 2007 to 2010 and FlowCardia, Inc., a chronic total occlusion device company, from 2004 to 2010. Mr. Stautberg received a B.B.A. degree from the University of Cincinnati and has completed executive programs at Columbia University.

Michael Carusi

 Mr. Michael A. Carusi is an Independent Director of TranS1 Inc. He has served as a General Partner at Advanced Technology Ventures, a venture capital firm, since October 1998. Mr. Carusi serves on the board of directors of GI Dynamics, which is listed on the Australian Securities Exchange. Mr. Carusi has also served on the board of XTENT, Inc., which was a public company until 2009. In addition, he serves on the boards, audit committees and compensation committees of several other privately-held life sciences and medical device companies. Mr. Carusi received a B.S. degree in Mechanical Engineering from Lehigh University and an M.B.A. degree from the Amos Tuck School of Business at Dartmouth College.

Jeffrey Fischgrund

 Dr. Jeffrey Fischgrund, M.D., is Independent Director of TranS1 Inc. Dr. Fischgrund, is a board certified orthopedic spine surgeon with over 20 years of experience. Dr. Fischgrund is a Professor of Orthopedic Surgery at The Oakland University School of Medicine, at William Beaumont Hospital in Royal Oak, Michigan. In addition, Dr. Fischgrund has served as the Editor in Chief of the Journal of the American Academy of Orthopedic Surgeons since 2009, and has been the Spine Fellowship Director at Beaumont Hospital since 2008. Dr. Fischgrund is a graduate of George Washington University School of Medicine in Washington, D.C., has completed an orthopedic surgery residency at the University of Maryland Medical Center in Baltimore, Maryland, and has completed a spine surgery fellowship at William Beaumont Hospital in Royal Oak, Michigan.

Jonathan Osgood

 Mr. Jonathan Osgood is an Independent Director of TranS1 Inc. In 2001, Mr. Osgood co-founded, and is a managing member of, Cutlass Capital, L.L.C., a venture capital firm that invests exclusively in the healthcare industry. Mr. Osgood has served as a member of the board of directors of several privately-held medical device companies and as a member of the audit committee and compensation committee of several of such companies. Mr. Osgood is a Certified Financial Analyst and received a B.A. degree in Economics from Dartmouth College and an M.B.A. degree from the Amos Tuck School of Business at Dartmouth College.

James Shapiro

 Mr. James M. Shapiro is an Independent Director of TranS1 Inc. Mr. Shapiro has served as a General Partner of Kearny Venture Partners, a venture capital firm, and its predecessor, Thomas Weisel Healthcare Venture Partners, since March 2003. Since January 2000, Mr. Shapiro has also been a General Partner of ABS Healthcare Ventures. Mr. Shapiro serves on the board and audit committee of Hansen Medical, Inc., a publicly traded medical device company, as well as on the boards and committees of several privately-held medical device companies. Mr. Shapiro received an A.B. degree in Molecular Biology from Princeton University and an M.B.A degree from the Stanford University Graduate School of Business.

David Simpson

 Mr. David J. Simpson is an Independent Director of TranS1 Inc. Mr. Simpson served as a director of Kinetic Concepts, a public medical technology company, from June 2003 to November 2011. He also served as a director of RTI Biologics, a public medical technology company, from 2002 to 2010. Mr. Simpson served as the chairperson of the board and as a member of the audit committees of both RTI Biologics and Kinetic Concepts. From 2002 until his retirement in 2007, Mr. Simpson served as Executive Vice President of Stryker Corporation, a worldwide medical products and services company. From 1987 to 2002, he served as Vice President, Chief Financial Officer and Secretary of Stryker Corporation. Mr. Simpson has a B.B.A. degree in accounting and finance from Western Michigan University and is a graduate of the Advanced Management Program at Harvard Business School.

Insider Trading

Name Shares Traded Price

REALI KENNETH MICHAEL

 2,000 $2.60

REALI KENNETH MICHAEL

 3,500 $2.56

REALI KENNETH MICHAEL

 1,160 $2.55

REALI KENNETH MICHAEL

 340 $2.63

SLATTERY JOSEPH P

 48,420 $1.50

SLATTERY JOSEPH P

 85,000 $1.50

DELPHI MANAGEMENT PARTNERS VIII L L C

 1,523,584 $3.25

SIMPSON DAVID J

 50,000 $3.25

CARUSI MICHAEL A

 37,667 $3.25

ATV ASSOCIATES VII L L C

 5,594 $3.25

DELPHI MANAGEMENT PARTNERS VIII L L C

 14,877 $3.25

ATV ASSOCIATES VII L L C

 37,667 $3.25

CARUSI MICHAEL A

 18,105 $3.25

CARUSI MICHAEL A

 938,634 $3.25

ATV ASSOCIATES VII L L C

 938,634 $3.25

CARUSI MICHAEL A

 5,594 $3.25

ATV ASSOCIATES VII L L C

 18,105 $3.25

SLATTERY JOSEPH P

 15,000 $3.25

RANDALL RICHARD D

 19,700 $4.85

RANDALL RICHARD D

 300 $4.80
» Full list on Insider Trading
Search Stocks